CMS certification 450690
University of Texas Health Science Center at Tyler
11937 US Highway 271, Tyler, TX 75708
University of Texas Health Science Center at Tyler has a CMS overall rating of 4 out of 5 stars. 81% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 11 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none. Emergency patients spend a median of 2 h 33 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 142 completed surveys, 17% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as low; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | TX | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 337 visits sampled · US median for EDs of the same volume: 2 h 3 min | 2 h 33 min | 2 h 25 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 45 visits sampled | 5 h 9 min | 3 h 53 min | 4 h 17 min |
| Left before being seen Lower is better · 10,398 patients | 1% | 1% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 30 patients | 77% | 68% | 65% |
How University of Texas Health Science Center at Tyler compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| University of Texas Health Science Center at TylerThis hospital | 4/5 | 81% | 2 h 33 min | 1 better |
| Baylor Scott & White Texas Spine & Joint HospitalSame city | 5/5 | 86% | 2 h 32 min | 1 worse |
| CHRISTUS Mother Frances HospitalSame city | 4/5 | 75% | 1 h 42 min | 8 better 2 worse |
| Ut Health East Texas Tyler Regional HospitalSame city | 2/5 | 67% | 2 h 36 min | 1 better 6 worse |
| Ut Health East Texas Athens HospitalSame ZIP area · Athens | 2/5 | 72% | 2 h 35 min | 1 better 3 worse |
| CHRISTUS Mother Frances Hospital- JacksonvilleSame ZIP area · Jacksonville | Not rated | 92% | 1 h 36 min | 1 better |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Tyler.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 231 cases | Too few cases | 4.2% | 3.9% |
| Heart failure 45 cases | Too few cases | 11.7% | 11.1% |
| Pneumonia 72 cases | Too few cases | 15% | 15.2% |
4 more measures had too few cases here to report.
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Pressure ulcers (bed sores) 342 cases | No different | 0.57 per 1,000 likely 0 per 1,000 – 1.86 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 453 cases | No different | 0.21 per 1,000 likely 0 per 1,000 – 0.44 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 467 cases | No different | 0.27 per 1,000 likely 0.05 per 1,000 – 0.49 per 1,000 | 0.27 per 1,000 |
10 more measures had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 1.94 likely 0.33 – 6.4 | 1 |
| C. diff intestinal infections | No different | 0 | 1 |
4 more measures had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after heart failure 81 cases | Too few cases | 20.9% | 21.3% |
| Readmitted after pneumonia 114 cases | Too few cases | 16.3% | 17.3% |
| Readmitted after COPD 40 cases | Too few cases | 19.1% | 20% |
| Days back in hospital after heart failure 50 cases | Too few cases | -11.2 days per 100 | — |
| Days back in hospital after pneumonia 67 cases | Too few cases | -56.6 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 440 cases | No different | 13.1 per 1,000 likely 9.9 per 1,000 – 17.4 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 381 cases | No different | 11.5 per 100 likely 9.1 per 100 – 14.3 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 381 cases | No different | 4.9 per 100 likely 3.6 per 100 – 6.7 per 100 | 5.4 per 100 |
6 more measures had too few cases here to report.
Clinicians registered at this address
261 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 207 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Family Medicine | 35 |
| Psychiatry | 27 |
| Internal Medicine | 22 |
| Occupational Medicine | 11 |
| Dietitian, Registered | 9 |
| Pharmacist | 9 |
| Pulmonary Disease | 9 |
| Emergency Medicine | 8 |
| Family | 8 |
| Clinical | 6 |
| Diagnostic Radiology | 6 |
| Health Educator | 6 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $339,581
- 2020 $682,173
- 2021 $1.3M
- 2022 $2M
- 2023 $2.2M
- 2024 $1.7M
- 2025 $1.6M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $204,985 | 2 |
| Space rental and facility fees | $12,500 | 4 |
| Speaking, teaching and other services | $2,500 | 1 |
| Debt forgiveness | $1,565 | 3 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Genentech, Inc. | $360,585 | 38 |
| Merck Sharp & Dohme LLC | $324,439 | 3 |
| Insmed, Inc. | $214,180 | 74 |
| E.R. Squibb & Sons, L.L.C. | $102,938 | 6 |
| Janssen Research & Development, LLC | $81,430 | 9 |
| Sanofi US Services INC. | $80,952 | 4 |
| Pfizer INC. | $71,412 | 19 |
| F. Hoffmann-La Roche AG | $59,937 | 11 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inha… Insmed, Inc. · NCT04677569 | $214,180 |
| UC P3: Double-Blind Treat Straight Through Genentech, Inc. | $139,583 |
| An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects w… Merck Sharp & Dohme LLC | $121,400 |
| An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in … Merck Sharp & Dohme LLC | $103,246 |
| A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Trea… Merck Sharp & Dohme LLC | $99,793 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepe… SANOFI US SERVICES INC. · NCT06280391 | $80,952 |
| A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as … E.R. Squibb & Sons, L.L.C. | $73,858 |
| AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPA… PFIZER INC. | $67,309 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about University of Texas Health Science Center at Tyler
Is University of Texas Health Science Center at Tyler a good hospital?
University of Texas Health Science Center at Tyler has a CMS overall rating of 4 out of 5 stars. Of the 11 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on none. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend University of Texas Health Science Center at Tyler?
81% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 142 completed HCAHPS surveys.
How long is the wait in the University of Texas Health Science Center at Tyler emergency room?
Emergency patients spend a median of 2 h 33 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with low patient volume, like this one, the median is 2 h 3 min. 1% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does University of Texas Health Science Center at Tyler receive money from drug and device companies?
Drug and device makers reported $1.6M in payments to University of Texas Health Science Center at Tyler for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.